InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: moneycrew post# 159367

Friday, 04/16/2021 5:57:33 PM

Friday, April 16, 2021 5:57:33 PM

Post# of 233646

another MAB which is like Lenzil ( the next to fail) is done


Next to fail? Its trial was a success. 54% efficacy on the whole trial. Bamlanivimab not being effective means lenzilumab has one less competitor. The Merck drug for severe also just said that they're not going to use it for hospitalized patients because of inefficacy. Those were lenz's main 2 competitors for severe patients. So lenz is on the cusp of an EUA and its 2 main competitors are bowing out. Sounds like the FDA is going with lenz as the Standard Of Care.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News